Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been published in the Journal of Health Economics and Outcomes ...

If you have prostate cancer and radiation therapy is an option, how to choose which type is right for your situation? The answer lies in a discussion with your doctor about the pluses and minuses of ...

Hypofractionation of radiation therapy in men with high-risk prostate cancer is not associated with worse overall survival or prostate cancer mortality. Survival outcomes are comparable after ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

GRAND RAPIDS, Mich. — 3.3 million American men live with prostate cancer, according to Zero Prostate Cancer. That makes it the most commonly diagnosed cancer for men in the U.S. There is a fairly new ...

Alpha Tau Medical Ltd ($DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is ...

(Reuters Health) - Elderly men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even patients who may be too old to benefit from the ...

Physicians who treat patients with high-risk prostate cancer remain uncertain as to the optimal treatment approach, in part due to difficulty in interpreting study data. High-risk prostate cancer (PCa ...

Data from previous studies have been mixed on whether risk for rectal cancer increases after prostate radiation. In this study, researchers evaluated a retrospective cohort of prostate cancer patients ...